Home/Filings/4/0001725160-22-000034
4//SEC Filing

Pinto Alexis 4

Accession 0001725160-22-000034

CIK 0001725160other

Filed

Feb 13, 7:00 PM ET

Accepted

Feb 14, 9:10 PM ET

Size

11.1 KB

Accession

0001725160-22-000034

Insider Transaction Report

Form 4
Period: 2022-02-10
Pinto Alexis
Chief Legal Officer
Transactions
  • Award

    Common Stock

    2022-02-10+16,40522,931 total
  • Award

    Stock Option (Right to Buy)

    2022-02-10+38,48938,489 total
    Exercise: $52.61Exp: 2032-02-09Common Stock (38,489 underlying)
  • Sale

    Common Stock

    2022-02-14$50.16/sh614$30,80122,317 total
  • Sale

    Common Stock

    2022-02-14$50.75/sh77$3,90822,240 total
Footnotes (5)
  • [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
  • [F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
  • [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.

Issuer

Zentalis Pharmaceuticals, Inc.

CIK 0001725160

Entity typeother

Related Parties

1
  • filerCIK 0001819302

Filing Metadata

Form type
4
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 9:10 PM ET
Size
11.1 KB